| Literature DB >> 19925426 |
P Anthony Akkari1, Thomas W Swanson, Donna G Crenshaw, Iris Grossman, Scott Sundseth, Daniel K Burns, Allen D Roses.
Abstract
There has been a decline in the number of new drugs registered over the past decade and regulatory concerns for safety as well as payer concerns for efficacy have focused attention on stratified medicine. Integration of pharmacogenetics into the drug development pipeline will contribute to the development of new stratified drugs. We describe here the concept of pipeline pharmacogenetics and its application throughout the phases of drug discovery. Pipeline pharmacogenetics enables the evaluation of the genetic contribution to safety potentially lowering barriers to registration as well as providing rationale for efficacy and enabling co-development of genetic in vitro diagnostics.Mesh:
Year: 2009 PMID: 19925426 DOI: 10.2174/138161209789649538
Source DB: PubMed Journal: Curr Pharm Des ISSN: 1381-6128 Impact factor: 3.116